Welcome to our dedicated page for Nanobiotix news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix stock.
Nanobiotix S.A. develops nanotechnology-based therapeutic platforms for cancer and other major diseases as a late-stage clinical biotechnology company. Its news commonly centers on JNJ-1900 (NBTXR3), a hafnium oxide nanoparticle radioenhancer administered by intratumoral injection and activated by radiotherapy, including head and neck cancer and lung cancer development updates, clinical data presentations, and regulatory communications.
Company updates also cover the Nanoprimer platform for bioavailability and biodistribution, preclinical work with lipid nanoparticle-delivered therapies, collaborations with Johnson & Johnson, Janssen and MD Anderson, periodic operating and financial results, and recurring disclosures of share capital and voting rights for its Euronext Paris and Nasdaq-listed securities.
Nanobiotix has reported its voting rights and share count as of November 30, 2021. The company has 34,825,872 shares outstanding, with a total of 36,003,389 voting rights (gross) and 35,985,166 voting rights (net). This information aligns with regulatory requirements set by the French Financial Markets Authority.
Nanobiotix, listed on both Euronext Paris and Nasdaq, specializes in innovative therapeutic approaches in biotechnology, focusing on oncology and has market authorization for its lead candidate, NBTXR3.
NANOBIOTIX (NASDAQ: NBTX), a late-stage biotechnology company focusing on innovative cancer treatments, announced participation by CEO Laurent Levy in a virtual fireside chat at the Evercore ISI HealthCONx Conference on December 2, 2021, at 1:00 PM EST. The live audio webcast will be accessible on the company’s website, with an archived recording available for 90 days. NANOBIOTIX, founded in 2003 and headquartered in Paris, is known for its physics-based therapeutic approaches and has market authorization for its product NBTXR3 in Europe.
NBTXR3, developed by Nanobiotix, shows promising preclinical results presented at the 36th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC). The data indicate that radiotherapy-activated NBTXR3 enhances CD8+ T cell infiltration and modulates the T cell receptor repertoire, suggesting improved immune priming. Additionally, the combination of NBTXR3 with anti-PD-1, anti-LAG3, and anti-TIGIT substantially elevated anti-tumor immune response activities. These findings underscore potential advancements in combination therapies for solid tumors.
Nanobiotix announced its latest regulatory update as of October 31, 2021, reporting a total of 34,825,872 shares outstanding. The gross total number of voting rights is 36,003,389, while the net total is 35,983,625. This update is in compliance with the French Commercial Code and aims to ensure transparency in shareholder communications. Established in 2003, the company focuses on innovative therapeutic solutions in oncology, with its lead candidate NBTXR3 already authorized in Europe for treating soft tissue sarcoma.
Nanobiotix, a late-stage biotechnology company specializing in innovative cancer treatments, announced CEO Laurent Levy's participation in a fireside chat at the Jefferies London Healthcare Conference. Scheduled for November 16, 2021, at 3:40 PM GMT/10:40 AM EST, the event will be live-streamed on the company's website. Established in 2003, Nanobiotix focuses on physics-based therapies and holds over 30 patents. Its lead product, NBTXR3, is authorized in Europe for soft tissue sarcoma under the brand name Hensify®.
Nanobiotix has released first survival data from its NBTXR3 program at the ASTRO 2021 Annual Meeting. In a group of 41 elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC), the median overall survival (mOS) was 18.1 months and median progression-free survival (mPFS) was 10.6 months. The best objective response rate (ORR) was 85.4%, with a complete response rate (CRR) of 63.4%. These positive findings support future phase III trials aimed at this challenging patient group.
Nanobiotix (NASDAQ: NBTX) reported progress in its oncology clinical programs, highlighting published preclinical data in the Red Journal about NBTXR3 combined with radiotherapy and anti-PD-1. The company is set to present survival data from its head and neck cancer program at the ASTRO meeting from October 24-27, 2021. As of September 30, 2021, Nanobiotix had €89.8 million in cash. It is on track to activate clinical trial sites for its pivotal phase III study, NANORAY-312, in the coming weeks.
Nanobiotix announces its total number of shares and voting rights as of September 30, 2021. The company had 34,825,872 outstanding shares with 35,999,889 total voting rights gross and 35,986,273 total voting rights net. This report complies with the French Commercial Code and the General Regulations of the Autorité des Marchés Financiers. As a clinical biotechnology company, Nanobiotix focuses on innovative therapeutic approaches in oncology with its lead candidate NBTXR3 already authorized in Europe for treating soft tissue sarcoma under the brand name Hensify®.
NANOBIOTIX (NASDAQ: NBTX) announced five presentations at the ASTRO 2021 Annual Meeting, from October 24-27. Key highlights include:
- Poster presentation by Pr. Christophe Le Tourneau on phase I data for NBTXR3 in head and neck cancer.
- Oral presentation by Dr. Tanguy Y. Seiwert discussing NBTXR3's potential effects as a single agent and with anti-PD-1.
- Dr. Sylvie Bonvalot's follow-up on phase II/III STS study.
NBTXR3, a novel oncology product, is designed for use with radiotherapy, showing promise in treating solid tumors.
Nanobiotix (NASDAQ: NBTX) announced the publication of preclinical data in the International Journal of Radiation Oncology, showcasing the potential of NBTXR3 combined with radiotherapy and anti-PD-1 to enhance tumor treatment. The study reveals that NBTXR3 effectively controls tumor growth in both sensitive and resistant models, improves immune response, and reduces metastasis. This research supports NBTXR3's exploration as a novel treatment option for metastatic lung cancer, aiming to convert irradiated tumors into 'self-vaccines' for broader therapeutic use.